Protecting the intellectual property of new drugs is complicated but essential for pharmaceutical companies. Patents are important in this respect, but by themselves they do not always create a sufficiently favourable environment for encouraging drug development.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
Patent, FDA, NME, Taiwanese Pharmaceutical Affairs Act, Hatch-Waxman Act, pharmaceuticals
